Skip to main content

Table 2 Association between MDM2 SNP309 status and clinicopathological characteristics

From: Association of TP53codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

 

Total, n (percent)

T/T, n (percent)

T/G, n (percent)

T/T + T/G, n (percent)

G/G, n (percent)

P a

Patients

557 (100)

111 (20)

263 (47)

374 (67)

183 (33)

 

Age (median, year) (n = 557)

 

57

56

56

58

 

Tumor size (n = 557)

     

0.49

   ≤ 2 cm

202 (36)

49 (44)

88 (33)

137 (37)

65 (36)

 

   2 cm to ≤ 5 cm

286 (51)

53 (48)

139 (53)

192 (51)

94 (51)

 

   >5 cm

57 (10)

6 (5)

28 (11)

34 (9)

23 (12)

 

   Unknown

12 (2)

3 (3)

8 (3)

11 (3)

1 (1)

 

Node status (n = 557)

     

0.63

   Negative

321 (58)

59 (53)

159 (60)

218 (58)

103 (56)

 

   Positive

198 (35)

42 (38)

88 (34)

130 (35)

68 (37)

 

   Unknown

38 (7)

10 (9)

16 (6)

26 (7)

12 (7)

 

Histology (n = 557)

     

0.44

   IDC

486 (87)

97 (87)

233 (89)

330 (88)

156 (85)

 

   ILC

20 (4)

3 (3)

8 (3)

11 (3)

9 (5)

 

   Others

51 (9)

11 (10)

22 (8)

33 (9)

18 (10)

 

ER status (n = 557)

     

0.14

   Positive

344 (62)

68 (61)

153 (58)

221 (59)

123 (67)

 

   Negative

181 (32)

33 (30)

95 (36)

128 (34)

53 (29)

 

   Unknown

32 (6)

10 (9)

15 (6)

25 (7)

7 (4)

 

Grade (n = 289)

     

0.19

   1

71 (24)

19 (31)

36 (26)

55 (27)

16 (18)

 

   2

147 (51)

29 (47)

66 (47)

95 (47)

52 (60)

 

   3

54 (19)

10 (16)

29 (21)

39 (19)

15 (17)

 

   Unknown

17 (6)

4 (6)

9 (6)

13 (6)

4 (5)

 

p53 IHC (n = 289)

     

>0.99

   Positive

72 (25)

19 (31)

31 (22)

50 (25)

22 (25)

 

   Negative

196 (68)

41 (66)

95 (68)

136 (67)

60 (69)

 

   Unknown

21 (7)

2 (3)

14 (10)

16 (8)

5 (6)

 
  1. aT/T + T/G genotypes versus G/G genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma.